Next Article in Journal / Special Issue
Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells
Previous Article in Journal
Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells
Previous Article in Special Issue
Inhibition of Pannexin 1 Reduces the Tumorigenic Properties of Human Melanoma Cells
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Cancers 2019, 11(1), 109; https://doi.org/10.3390/cancers11010109

Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1

1
Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, 72076 Tuebingen, Germany
2
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, 70376 Stuttgart, Germany
3
University of Tuebingen, 72076 Tuebingen, Germany
4
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
5
Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany
*
Author to whom correspondence should be addressed.
Received: 14 December 2018 / Revised: 10 January 2019 / Accepted: 13 January 2019 / Published: 17 January 2019
(This article belongs to the Special Issue Ion Channels in Cancer)
Full-Text   |   PDF [1600 KB, uploaded 22 January 2019]   |  

Abstract

Several tumor entities have been reported to overexpress KCa3.1 potassium channels due to epigenetic, transcriptional, or post-translational modifications. By modulating membrane potential, cell volume, or Ca2+ signaling, KCa3.1 has been proposed to exert pivotal oncogenic functions in tumorigenesis, malignant progression, metastasis, and therapy resistance. Moreover, KCa3.1 is expressed by tumor-promoting stroma cells such as fibroblasts and the tumor vasculature suggesting a role of KCa3.1 in the adaptation of the tumor microenvironment. Combined, this features KCa3.1 as a candidate target for innovative anti-cancer therapy. However, immune cells also express KCa3.1 thereby contributing to T cell activation. Thus, any strategy targeting KCa3.1 in anti-cancer therapy may also modulate anti-tumor immune activity and/or immunosuppression. The present review article highlights the potential of KCa3.1 as an anti-tumor target providing an overview of the current knowledge on its function in tumor pathogenesis with emphasis on vasculo- and angiogenesis as well as anti-cancer immune responses. View Full-Text
Keywords: KCa3.1; intermediate conductance calcium-activated K+ channel; BK; big conductance Ca2+- and voltage-activated K+ channels; TRAM-34; (1-[(2-chlorophenyl) diphenylmethyl]-pyrazole; 1-EBIO; 1-Ethyl-1,3-dihydro-2H-benzimidazol-2-one; E2; 17β-estradiol KCa3.1; intermediate conductance calcium-activated K+ channel; BK; big conductance Ca2+- and voltage-activated K+ channels; TRAM-34; (1-[(2-chlorophenyl) diphenylmethyl]-pyrazole; 1-EBIO; 1-Ethyl-1,3-dihydro-2H-benzimidazol-2-one; E2; 17β-estradiol
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Mohr, C.J.; Steudel, F.A.; Gross, D.; Ruth, P.; Lo, W.-Y.; Hoppe, R.; Schroth, W.; Brauch, H.; Huber, S.M.; Lukowski, R. Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1. Cancers 2019, 11, 109.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top